Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Allergo Journal
Literatur
1.
Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64
2.
de Monchy JG, Demoly P, Akdis CA, Cardona V, Papadopoulos NG, Schmid-Grendelmeier P et al. Allergology in Europe, the blueprint. Allergy 2013;68:1211-8
3.
Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Canonica WG et al. Allergic rhinitis. Nat Rev Dis Primers 2020;6:95
4.
Shin YH, Hwang J, Kwon R, Lee SW, Kim MS, GBD 2019 Allergic Disorders Collaborators et al. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. Allergy 2023;78:2232-54
5.
Abbas M, Moussa M, Akel H. Type I Hypersensitivity Reaction. StatPearls, Treasure Island (FL): StatPearls Publishing; 2024.
6.
Jutel M, Agache I, Zemelka-Wiacek M, Akdis M, Chivato T, Del Giacco S et al. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper. Allergy 2023;78:2851-74
7.
Pfaar O, Creticos PS, Kleine-Tebbe J, Canonica GW, Palomares O, Schülke S. One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. J Allergy Clin Immunol Pract 2021;9:1791-803
8.
Wheeler AW, Woroniecki SR. Allergy vaccines - new approaches to an old concept. Expert Opin Biol Ther 2004;4:1473-81
9.
Satitsuksanoa P, Angelina A, Palomares O, Akdis M. Mechanisms in AIT: Insights 2021. Allergol Select 2022;6:259-66
10.
Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol1998;102:558-62
11.
Pfaar O, Ankermann T, Augustin M, Bubel P, Böing S, Brehler R et al. Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the DGAKI, GPA, AeDA, ÖGAI, SSAI, DDG, DGHNO-KHC, DGKJ, GPP, DGP, BVHNO, BVKJ, BdP, BVDD. Allergol Select 2022;6:167-232
12.
Pfaar O, Becker S, Calabria C, Hartenstein D, Jung J, Zimmer J et al. Comparison of allergen immunotherapy practice patterns in inhalant allergies in the United States of America and Europe: Similarities and differences 2023. World Allergy Organ J 2023;16:100766
13.
Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy 2012;2:2
14.
Liu J, Li W, Zhu R. The Role of Innate Immune Cells in Allergen Immunotherapy. Curr Treat Options Allergy 2023;10:148-65
15.
Golebski K, Layhadi JA, Sahiner U, Steveling-Klein EH, Lenormand MM, Li RCY et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity 2021;54:291-307.e7
16.
Mitthamsiri W, Pradubpongsa P, Sangasapaviliya A, Boonpiyathad T. Decreased CRTH2 Expression and Response to Allergen Re-stimulation on Innate Lymphoid Cells in Patients With Allergen-Specific Immunotherapy. Allergy Asthma Immunol Res 2018;10:662-74
17.
Eljaszewicz A, Ruchti F, Radzikowska U, Globinska A, Boonpiyathad T, Gschwend A, et al. Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy. J Allergy Clin Immunol 2020;147:1865-77
18.
Committee For Medicinal Products For Human Use (CHMP): Guideline OnAdjuvants InVaccines For Human Usecommittee For Medicinal Products For Human Use. EMEA/CHMP/VEG/134716/2004. London, 20 January 2005 n.d.
19.
Hem SL, White JL. Structure and properties of aluminum-containing adjuvants. Pharm Biotechnol 1995;6:249-76
20.
Cox JC, Coulter AR. Adjuvants - a classification and review of their modes of action. Vaccine 1997;15:248-56
21.
Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol 2013;4:114
22.
Leuthard DS, Duda A, Freiberger SN, Weiss S, Dommann I, Fenini G et al. Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling. J Immunol 2018;200:3151-9
23.
Lin Y-J, Zimmermann J, Schülke S. Novel adjuvants in allergen-specific immunotherapy: where do we stand? Front Immunol 2024;15:1348305
24.
Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes. XVII-XXIV. J Pathol and Bacteriol 1926;29:31-40
25.
Council of Europe; Strasbourg, France, 2024. EDQM. European Pharmacopoeia. 11.4th edition. n.d.
26.
HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002;20 Suppl 3:34-9
27.
Jensen-Jarolim E. Aluminium in Allergies and Allergen immunotherapy. World Allergy Organ J 2015;8:7
28.
Kooijman S, Brummelman J, van Els CACM, Marino F, Heck AJR, van Riet E et al. Vaccine antigens modulate the innate response of monocytes to Al(OH)3. PLoS One 2018;13:e0197885
29.
Fadugba OO, Wang L, Chen Q, Halasa NB. Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine. Clin Vaccine Immunol 2014;21:1613-9
30.
Benito-Villalvilla C, Pérez-Diego M, Angelina A, Kisand K, Rebane A, Subiza JL et al. Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring. J Allergy Clin Immunol 2022;149:212-222.e9
31.
McKee AS, Munks MW, MacLeod MKL, Fleenor CJ, Van Rooijen N, Kappler JW et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009;183:4403-14
32.
Kool M, Soullié T, van Nimwegen M, Willart MAM, Muskens F, Jung S et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205:869-82
33.
Mannhalter JW, Neychev HO, Zlabinger GJ, Ahmad R, Eibl MM. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol 1985;61:143-51
34.
Iyer S, HogenEsch H, Hem SL. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine 2003;21:1219-23
35.
Rimaniol A-C, Gras G, Verdier F, Capel F, Grigoriev VB, Porcheray F et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 2004;22:3127-35
36.
Lindblad EB Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82:497-505
37.
Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:1122-6
38.
Kool M, Pétrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008;181:3755-9
39.
Franchi L, Núñez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008;38:2085-9
40.
Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011;34:514-26
41.
Kool M, Willart MAM, van Nimwegen M, Bergen I, Pouliot P, Virchow JC et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 2011;34:527-40
42.
McDougall SA, Heath MD, Kramer MF, Skinner MA. Analysis of aluminium in rat following administration of allergen immunotherapy using either aluminium or microcrystalline-tyrosine-based adjuvants. Bioanalysis 2016;8:547-56
43.
Jensen-Jarolim E, Bachmann MF, Bonini S, Jacobsen L, Jutel M, Klimek L et al. State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy 2020;75:746-60
44.
45.
Weisser K, Stübler S, Matheis W, Huisinga W. Towards toxicokinetic modelling of aluminium exposure from adjuvants in medicinal products. Regul Toxicol Pharmacol 2017;88:310-21
46.
Hethey C, Hartung N, Wangorsch G, Weisser K, Huisinga W. Physiology-based toxicokinetic modelling of aluminium in rat and man. Arch Toxicol 2021;95:2977-3000
47.
Hiller J, Göen T, Drexler H, Berking C, Wagner N. Elevated aluminum excretion in patients by long-term subcutaneous immunotherapy - A cross-sectional case-control study. Int J Hyg Environ Health 2024;258:114337
48.
Mahler V, Kleine-Tebbe J, Vieths S. [Immunotherapy of allergies: current status]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:1341-56
49.
Baldrick P, Richardson D, Wheeler AW. Review of L-tyrosine confirming its safe human use as an adjuvant. J Appl Toxicol 2002;22:333-44
50.
Bell AJ, Heath MD, Hewings SJ, Skinner MA. The adsorption of allergoids and 3-O-desacyl-4'-monophosphoryl lipid A (MPL®) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy. J Inorg Biochem 2015;152:147-53
51.
Heath MD, Mohsen MO, de Kam P-J, Carreno Velazquez TL, Hewings SJ, Kramer MF, et al. Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®). Front Immunol 2020;11:594911
52.
Miller AC, Hart AP, Tees EC. D. pteronyssinus-tyrosine adsorbate: biological and clinical properties. Acta Allergol 1976;31:35-43
53.
He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJ. Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol 2000;7:899-903
54.
Jones S, Asokanathan C, Kmiec D, Irvine J, Fleck R, Xing D et al. Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity. Vaccine 2014;32:4234-42
55.
Leynadier F, Banoun L, Dollois B, Terrier P, Epstein M, Guinnepain MT, et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2001;31:988-96
56.
Pazár B, Ea H-K, Narayan S, Kolly L, Bagnoud N, Chobaz V, et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J Immunol 2011;186:2495-502
57.
Hayashi M, Aoshi T, Kogai Y, Nomi D, Haseda Y, Kuroda E et al. Optimization of physiological properties of hydroxyapatite as a vaccine adjuvant. Vaccine 2016;34:306-12
58.
Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995;6:495-524
59.
Schülke S, Flaczyk A, Vogel L, Gaudenzio N, Angers I, Löschner B et al. MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS. Allergy 2015;70:1259-68
60.
Boland G, Beran J, Lievens M, Sasadeusz J, Dentico P, Nothdurft H et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004;23:316-20
61.
RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015;386:31-45
62.
Mahler V, Bonertz A, Ruoff C, Hartenstein D, Mentzer D, Kaul S et al. What we learned from TAO - 10 years of German therapy allergen ordinance. Allergo J Int 2019;28:330-7
63.
Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPLR)* promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005;60:678-84
64.
Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498-505
65.
Worm M, Higenbottam T, Pfaar O, Mösges R, Aberer W, Gunawardena K et al. Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy. Allergy 2018;73:1812-22
66.
de Kam PJ, Zielen S, Bernstein JA, Berger U, Berger M, Cuevas M et al. Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy. Allergy 2023;78:2756-66
67.
Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001;126:135-9
68.
Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol 2014;133:121-129.e1-2
69.
Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol (Madr) 2003;31:270-7
70.
Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:1198-208
71.
Sheng K-C, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 2006;118:372-83
72.
Sánchez-Herrero S, Benito-Villalvilla C, Palomares O. Purified Free Mannan Promotes Tolerogenic Responses in Peanut-Stimulated Human Dendritic Cells. Int Arch Allergy Immunol 2024;185:652-8
73.
Sirvent S, Soria I, Cirauqui C, Cases B, Manzano AI, Diez-Rivero CM et al. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. J Allergy Clin Immunol 2016;138:558-67.e11
74.
Benito-Villalvilla C, Pérez-Diego M, Subiza JL, Palomares O. Allergoid-mannan conjugates imprint tolerogenic features in human macrophages. Allergy 2022;77:320-3
75.
Nieto A, Mazón Á, Nieto M, Ibáñez E, Jang D-T, Calaforra S et al. First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy. Allergy 2022;77:3096-107
76.
Mösges R, Zeyen C, Raskopf E, Acikel C, Sahin H, Allekotte S et al. A randomized, double-blind, placebo-controlled trial with mannan-conjugated birch pollen allergoids. Allergy 2024;79:990-1000
77.
Li S, Toriumi H, Takahashi D, Kamasaki T, Fujioka Y, Nagatoishi S et al. Safe and efficient oral allergy immunotherapy using one-pot-prepared mannan-coated allergen nanoparticles. Biomaterials 2023;303:122381
78.
Li S, Murakami D, Nagatoishi S, Liu Y, Tsumoto K, Katayama Y et al. One-pot preparation of mannan-coated antigen nanoparticles using human serum albumin as a matrix for tolerance induction. J Colloid Interface Sci 2023;649:955-65
79.
Johnson JE, Chiu W. Structures of virus and virus-like particles. Curr Opin Struct Biol 2000;10:229-35
80.
Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009;206:1941-55
81.
Sani MZ, Bargahi A, Momenzadeh N, Dehghani P, Moghadam MV, Maleki SJ et al. Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them. Appl Microbiol Biotechnol 2021;105:77-91
82.
Jitthamstaporn S, Sander AF, Jacquet A. Virus-like particles displaying recombinant Der p 1 zymogen to optimize IgG blocking antibody response. Allergy 2022;77:664-7
83.
Chanasit S, Johnston E, Thanasarnthungcharoen C, Kamath SD, Bohle B, Lopata AL et al. Hypoallergenic chimeric virus-like particles for the development of shrimp tropomyosin allergen Pen m 1-specific blocking antibodies. Allergy 2024;79:1052-5
84.
Soongrung T, Mongkorntanyatip K, Peepim T, Jitthamstaporn S, Pitakpolrat P, Kaewamatawong T, et al. Virus-like particles displaying major house dust mite allergen Der p 2 for prophylactic allergen immunotherapy. Allergy 2020;75:1232-6
85.
Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39:562-70
86.
Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011;41:1305-12
87.
Beeh K-M, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013;131:866-74
88.
Casale TB, Cole J, Beck E, Vogelmeier CF, Willers J, Lassen C et al. CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy 2015;70:1160-8
89.
Storni F, Zeltins A, Balke I, Heath MD, Kramer MF, Skinner MA et al. Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens. J Allergy Clin Immunol 2020;145:1240-1253.e3
90.
Sobczak JM, Krenger PS, Storni F, Mohsen MO, Balke I, Reseviča G et al. The next generation virus-like particle platform for the treatment of peanut allergy. Allergy 2023;78:1980-96
91.
Krenger PS, Josi R, Sobczak J, Velazquez TLC, Balke I, Skinner MA et al. Influence of antigen density and TLR ligands on preclinical efficacy of a VLP-based vaccine against peanut allergy. Allergy 2024;79:184-99
92.
Thoms F, Jennings GT, Maudrich M, Vogel M, Haas S, Zeltins A et al. Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. J Allergy Clin Immunol 2019;144:193-203
93.
Thoms F, Haas S, Erhart A, Nett CS, Rüfenacht S, Graf N et al. Immunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of Owners. Viruses 2020;12:288
94.
Goksøyr L, Funch AB, Okholm AK, Theander TG, de Jongh WA, Bonefeld CM et al. Preclinical Efficacy of a Capsid Virus-like Particle-Based Vaccine Targeting IL-1β for Treatment of Allergic Contact Dermatitis. Vaccines (Basel) 2022;10:828
95.
Kim J, Oh J, Kang C-S, Choi YS. Virus-like Particle (VLP) Mediated Antigen Delivery as a Sensitization Tool of Experimental Allergy Mouse Models. Immune Netw 2020;20:e35
96.
Kratzer B, Köhler C, Hofer S, Smole U, Trapin D, Iturri J et al. Prevention of allergy by virus-like nanoparticles (VNP) delivering shielded versions of major allergens in a humanized murine allergy model. Allergy 2019;74:246-60
97.
Pazos-Castro D, Margain C, Gonzalez-Klein Z, Amores-Borge M, Yuste-Calvo C, Garrido-Arandia M et al. Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines. Front Immunol 2022;13:986823
98.
Hatai H, Lepelley A, Zeng W, Hayden MS, Ghosh S. Toll-Like Receptor 11 (TLR11) Interacts with Flagellin and Profilin through Disparate Mechanisms. PLoS One 2016;11:e0148987
99.
Lee SE, Kim SY, Jeong BC, Kim YR, Bae SJ, Ahn OS et al. A Bacterial Flagellin , Vibrio vulnificus FlaB , Has a Strong Mucosal Adjuvant Activity To Induce Protective. Immunity 2006;74:694-702
100.
Honko AN, Sriranganathan N, Lees CJ, Mizel SB. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infection and Immunity 2006;74:1113-20
101.
Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007;25:763-75
102.
Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011;29:5145-52
103.
Tussey L, Strout C, Davis M, Johnson C, Lucksinger G, Umlauf S et al. Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins. Open Forum Infect Dis 2016;3:ofw015
104.
Kim EH, Kim JH, Samivel R, Bae J-S, Chung Y-J, Chung P-S et al. Intralymphatic treatment of flagellin-ovalbumin mixture reduced allergic inflammation in murine model of allergic rhinitis. Allergy 2016;71:629-39
105.
Bae SJ, Koh JT, Ryu H-J, Choy HE, Lee SE, Rhee JH et al. Inhibition of Airway Allergic Disease by Co-Administration of Flagellin with Allergen. J Clin Immunol 2007;28:157-65
106.
Shim J-U, Lee SE, Hwang W, Lee C, Park J-W, Sohn J-H et al. Flagellin suppresses experimental asthma by generating regulatory dendritic cells and T cells. J Allergy Clin Immunol 2016;137:426-35
107.
Li L-J, Ma N, Zeng L, Mo L-H, Li X-X, Xu L-Z et al. Flagellin modulates IgE expression in B cells to initiate food allergy in mice. Am J Transl Res 2016;8:2748-57
108.
Whitehead GS, Hussain S, Fannin R, Trempus CS, Innes CL, Schurman SH et al. TLR5 Activation Exacerbates Airway Inflammation in Asthma. Lung 2020;198:289-98
109.
Tan W, Zheng JH, Duong TMN, Koh YI, Lee SE, Rhee JH. A Fusion Protein of Derp2 Allergen and Flagellin Suppresses Experimental Allergic Asthma. Allergy Asthma Immunol Res 2019;11:254-66
110.
Kitzmüller C, Kalser J, Mutschlechner S, Hauser M, Zlabinger GJ, Ferreira F et al. Fusion proteins of flagellin and the major birch pollen allergen Bet v 1 show enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity. J Allergy Clin Immunol 2018;141:293-9.e6
111.
Schülke S, Burggraf M, Waibler Z, Wangorsch A, Wolfheimer S, Kalinke U et al. A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy. J Allergy Clin Immunol 2011;128:1340-8.e12
112.
Schülke S, Wolfheimer S, Gadermaier G, Wangorsch A, Siebeneicher S, Briza P et al. Prevention of intestinal allergy in mice by rflaA:Ova is associated with enforced antigen processing and TLR5-dependent IL-10 secretion by mDC. PLoS ONE 2014;9:e87822
113.
Schülke S, Kuttich K, Wolfheimer S, Duschek N, Wangorsch A, Reuter A et al. Author Correction: Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo. Sci Rep 2018;8:2745
114.
Schülke S, Fiedler A-H, Junker A-C, Flaczyk A, Wolfheimer S, Wangorsch A et al. Critical role of mammalian target of rapamycin for IL-10 dendritic cell induction by a flagellin A conjugate in preventing allergic sensitization. J Allergy Clin Immunol 2018;141:1786-98.e11
115.
Moeller T, Wolfheimer S, Goretzki A, Scheurer S, Schülke S. NFκB- and MAP-Kinase Signaling Contribute to the Activation of Murine Myeloid Dendritic Cells by a Flagellin A:Allergen Fusion Protein. Cells 2019;8:355
116.
Goretzki A, Lin Y-J, Zimmermann J, Rainer H, Junker A-C, Wolfheimer S et al. Role of Glycolysis and Fatty Acid Synthesis in the Activation and T Cell-Modulating Potential of Dendritic Cells Stimulated with a TLR5-Ligand Allergen Fusion Protein. Int J Mol Sci 2022;23:12695
117.
Mishra R, Sharma S, Arora N. TLR-5 ligand conjugated with Per a 10 and T cell peptides potentiates Treg/Th1 response through PI3K/mTOR axis. Int Immunopharmacol 2022;113(Pt A):109389
118.
Lin Y-J, Papp G, Miskey C, Fiedler A, Goretzki A, Wolfheimer S et al. The Flagellin:Allergen Fusion Protein rFlaA:Betv1 Induces a MyD88- and MAPK-Dependent Activation of Glucose Metabolism in Macrophages. Cells 2021;10:2614
119.
Lin Y-J, Jamin A, Wolfheimer S, Fiedler A, Junker A-C, Goretzki A et al. A flagellin-conjugate protein induces dual NLRC4- and NLRP3-inflammasome activation which modulates inflammatory cytokine secretion from macrophages. Front Immunol 2023;14:1136669
120.
Lin Y-J, Flaczyk A, Wolfheimer S, Goretzki A, Jamin A, Wangorsch A et al. The Fusion Protein rFlaA:Betv1 Modulates DC Responses by a p38-MAPK and COX2-Dependent Secretion of PGE2 from Epithelial Cells. Cells 2021;10:3415
121.
Goretzki A, Lin Y-J, Meier C, Dorn B, Wolfheimer S, Jamin A et al. Stimulation of naïve B cells with a fusion protein consisting of FlaA and Bet v 1 induces regulatory B cells ex vivo. Allergy 2023;78:663-81
Metadaten
Titel
Mannan-, VLP-, and flagellin-based adjuvants for allergen specific immunotherapy: a review of the current literature
verfasst von
Clara Pignard
Hannah Schiller
Alisa Seyffer
PD Dr. Stefan Schülke
Publikationsdatum
12.12.2024
Verlag
Springer Medizin
Erschienen in
Allergo Journal / Ausgabe 8/2024
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI
https://doi.org/10.1007/s15007-024-6396-9

Weitere Artikel der Ausgabe 8/2024

CRSwNP: Mepolizumab überzeugt in Real-World-Settings

Reform oder Reförmchen?

Toxicokinetics of aluminium - novel insights in an old adjuvant

Folgen des „Leberkäsetests“

  • Medizin aktuell

Empfehlungen des AeDA zur Auswahl von Therapieallergenen

Katzenallergie: Aktuelle Studie belegt Sicherheit der SCIT mit depigmentiertem Allergoid

Neu im Fachgebiet HNO

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Kopf-Hals-Tumore: Lebensqualität von Langzeitüberlebenden

Eine aktuelle Studie des Universitätsklinikums Erlangen verdeutlicht, dass Langzeitüberlebende von Kopf-Hals-Tumoren eine geringe Symptomlast aufweisen. Die am häufigsten auftretenden Beschwerden – Müdigkeit, Angstzustände, Schläfrigkeit und Schmerzen – sollten von den behandelnden Ärztinnen und Ärzten gezielt adressiert werden.

Schlafapnoe – es lag an einer verbogenen Nasenscheidewand

Tritt eine obstruktive Schlafapnoe vor allem in einer bestimmten Seitenlage auf, kann dies auch an einem verbogenen Nasenseptum liegen. Eine Septumplastik lindert die Beschwerden mitunter deutlich.

Das alles ändert sich für Arztpraxen in 2025

  • 31.12.2024
  • EBM
  • Nachrichten

Ab Januar greifen jede Menge Neuerungen – ob im EBM, Arbeits- und Steuerrecht oder bei der digitalen Vernetzung. Darunter einige Verbesserungen, aber teils auch Mehraufwand. „Same procedure as every year?“ – Ein Überblick.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise